MPN Hub

The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked, How might luspatercept benefit patients with myelofibrosis (MF)?  Aaron Gerds opens by discussing the prevalence and issue of anemia in patients with MF, noting that almost all patients will become anemic at some point in the course of their disease. Gerds discusses luspatercep...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the MPN Hub was pleased to speak with Haifa Kathrin Al-Ali, University Hospital Halle, Halle, DE. We asked, What more can be done to improve treatment for patients with polycythemia vera? Al-Ali provides an overview of how to improve treatment and outcomes for patients with polycythemia vera, opening with a discussion of the la...

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part II - Patients with myelofibrosis (MF). Patel opens by highlighting the need for more long-term effective MF treatments and presents long-term data on the cessation of existing therapi...

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part I — Patients with essential thrombocytopenia/polycythemia vera. In this podcast, Michaelis and Patel discuss the factors which determine whether standard of care treatment or referral...

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Laura Michaelis (Medical College of Wisconsin, Milwaukee, US) and Claire Harrison (Guy's and St Thomas' NHS Foundation Trust, London, UK). We asked, Patient follow-up in myeloproliferative neoplasms: Best practices and myths.  In this podcast, Michaelis and Harrison discuss the best practices in MPN, in par...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent polycythemia vera (PV)? Currently, patients with PV require frequent phlebotomy. Kremyanskaya discusses promising resu...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Jyoti Nangalia, University of Cambridge, Cambridge, UK. We asked, Should we consider early testing and treatment for driver mutations acquired in childhood? In this podcast, Jyoti Nangalia reports results from a study using next-generation sequencing to trace acquired MPN mutations in hematopoi...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms? Results from several studies have shown that interferon alpha is able to induce high rates of co...

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ghaith Abu-Zeinah, Weill Cornell Medicine, New York, US. We asked, Does interferon alpha prolong survival and prevent progression in patients with polycythemia vera (PV)? PV is a disease associated with shorter survival due to short-term complications, such as thrombosis, and long-term complica...

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee members Laura Michaelis, Medical College of Wisconsin, Milwaukee , US, and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What do we know about the outcome of concomitant MPN and COVID-19? In this podcast, Tiziano Barbui starts by giving some background to the COVID-19 pandemic in...

During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MPN Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft- versus -...